FY21 Forecast by Segment March 10, 2021

	(Billion ver							(Billion yen)	March 10, 202				
	FY21 Forecast	FY20 Results	YoY Change	FY20/9M Results	FY20/1H Results	FY20/3M Results	FY19 Results	FY18 Results	Reasons for YoY Change or Main Measures				
ıles	1,113.0	1,071.4	41.5	794.9	511.3	247.9	1,100.0	1,114.3	Seasonings and Foods Sauce & Seasonings: Increase in revenue expected primarily due to				
Seasonings and Foods	654.7	620.5	34.2	468.3	295.3	142.3	641.7	643.7	measures overseas to expand sales. Quick Nourishment: Increase in revenue expected due to expanded sa				
Sauce & Seasonings	308.8	288.9	19.8	217.9	140.3	65.7	293.0		of soup in Japan and increasing sales centered on instant noodles overseas.				
Quick Nourishment	197.5	186.3	11.1	139.6	83.5	41.0	193.6	193.4	S&I: Increase in revenue expected assuming a market recovery center on foodservice in Japan.				
Solution & Ingredients (S&I)	148.4	145.1	3.2	110.6	71.4	35.5	155.1	154.6	Frozen Foods				
Frozen Foods	208.2	198.2	9.9	149.6	98.8	48.2	211.2	213.0	In Japan, a decrease in revenue is expected due to the structural reforming restaurant-use products and key accounts, despite growth in home-to-				
Frozen Foods	208.2	198.2	9.9	149.6	98.8	48.2	211.2	213.0	producte				
Healthcare and Others	231.3	239.5	-8.1	167.4	110.6	54.0	231.6		foodservice market and the effect of increased production in Asian category products in North America.				
Bio-Pharma Services & Ingredients ²	101.0	91.4	9.5	59.9	41.6	20.0	89.6	86.0	Healthcare and Others				
Amino acids for pharmaceuticals and foods ³		42.5		31.0	21.5	11.0	41.0	40.5	Bio-Pharma Services & Ingredients: With a backdrop of a strong increase in demand, expanded sales and an increase in revenue expected for				
Bio-Pharma Services ⁴		49.0		28.5	20.0	9.0	48.5	45.5	amino acids for pharmaceuticals and foods. Increase in revenue expected for Bio-Pharma Services in view of stron market growth.				
Functional Materials ⁵	48.9	45.1	3.7	33.5	21.6	10.7	36.3	32.7	Functional materials: Increase in revenue expected in electronic mater due to expanded server and network applications, etc.				
Others	81.4	102.8	-21.4	73.9	47.3	23.2	105.6	124.4	Others: Significant decrease in revenue expected due to structural reforms in the animal nutrition business.				
Others	18.6	13.1	5.4	9.5	6.5	3.3	15.3	14.2					
siness Profit ¹	115.0	113.1	1.8	99.9	61.9	33.8	99.2	93.2	Seasonings and Foods Sauce & Seasonings: Increase in profit expected primarily due to				
Seasonings and Foods	85.8	86.7	-0.9	76.9	47.0	23.8	81.6	74.0	increased revenue overseas. Quick Nourishment: Overall, decrease in profit expected due to the				
Sauce & Seasonings	65.9	64.0	1.8	52.9	35.7	17.3	62.2		impact of starting up new factories in Japan, despite the effect of increased revenue from instant noodles overseas.				
Quick Nourishment	20.6	20.9	-0.2	19.4	9.7	4.7	16.8	16.2	S&I: Overall, decrease in profit expected with the drop in price of umar seasonings for processed food manufacturers and steep rise in raw				
Solution & Ingredients (S&I)	19.6	21.0	-1.4	18.4	11.0	6.5	22.8	19.5	material and fuel costs, despite the effect of increased revenue from foodservice-use products in Japan.				
Shared companywide expenses	-20.3	-19.2	-1.0	-13.7	-9.1	-4.4	-20.3	-20.6	Frozen Foods				
Frozen Foods	2.4	2.3	0.1	4.0	2.6	1.8	0.0		Increase in profit expected primarily due to the effect of increased revenue from North America.				
Frozen Foods	8.6	8.2	0.3	8.2	5.5	3.3	6.5	4.7	Healthcare and Others				
Shared companywide expenses	-6.1	-5.8	-0.2	-4.1	-2.8	-1.3	-6.5	-6.5	Bio-Pharma Services & Ingredients: Significant increase in profit expected due to increased revenue.				
Healthcare and Others	29.2	26.2	3.0	18.4	11.9	7.4	19.5	21.6	Functional materials: Increase in profit expected due to increased				
Bio-Pharma Services & Ingredients	13.8	11.9	1.8	6.8	5.0	2.9	13.7	11.9	revenues.				
Functional Materials	20.4	18.9	1.5	14.3	9.3	4.5	13.6	11.5	Others: Decrease in profit expected overall.				
Others	2.3	2.8	-0.5	2.2	1.0	1.6	-0.1	5.8					
Shared companywide expenses	-7.2	-7.4	0.1	-4.9	-3.3	-1.6	-7.7	-7.6					
Others	-2.6	-2.2	-0.3	0.6	0.2	0.5	-1.9	-0.6					
Shared companywide expenses	-1.6	-1.5	-0.1	-1.0	-0.7	-0.3	-2.2	-2.6					

Shared companywide expenses

1 A profit indicator defined by Ajinomoto for administrative purposes:

Sales - Cost of sales - Selling expenses, Research & development expenses and General & administrative expenses + Share of profit of associates and joint ventures 2 From FY2021, the Amino Acids sub-segment is called Bio-Pharma Services & Ingredients

3 From FY2021, the medical food business, which was included in amino acids for pharmaceuticals and foods, is included in the Others section of Healthcare and Others 4 From FY2021, the crop services business, which was included in Bio-Pharma Services, is included in the Others section of Healthcare and Others

5 From FY2021, the Specialty Chemicals sub-segment is called Functional Materials Notes: Nondisclosure (Italic) Approximation

(Reference) Sales Forecast by Business & Geographical Area

(Billion yen)

(Reference) Sales Forecast by Business & Geographical Area											
Sales	Japar	Japan		Asia		Americas		EMEA		Total	
Seasonings and Foods	280.1	(7.7)	268.5	(18.8)	73.7	(5.1)	32.2	(2.5)	654.7	(34.2)	
	272.4		249.7		68.5		29.7		620.5		
Frozen Foods	89.3	(-2.3)	3.5	(8.0)	104.1	(10.7)	11.1	(0.7)	208.2	(9.9)	
	91.7		2.6		93.4		10.3		198.2		
Healthcare and Others	101.4	(7.8)	7.3	(-3.8)	64.9	(7.8)	57.6	(-19.9)	231.3	(-8.1)	
	93.6		11.2		57.0		77.5		239.5		
Others	17.9	(4.9)	0.4	(0.3)	-	-	0.0	(0.0)	18.6	(5.4)	
	13.0		0.1		-		0.0		13.1		
Total	489.1	(18.2)	279.9	(16.1)	242.8	(23.7)	101.0	(-16.6)	1,113.0	(41.5)	
	470.8		263.7		219.0		117.7		1,071.4		

Upper row: FY21 forecast, lower row: FY20 results. Figures in parentheses represent difference.

of publication and do not represent a commitment from Ajinomoto Co., Inc. that they will be achieved. A number of factors could cause actual results to differ materially from expectations.

[·] Forward-looking statements, such as business performance forecasts, made in these materials are based on management's estimates, assumptions and projections at the time

[·] Unaudited figures are included in these materials for reference.